A randomized, open-label study evaluating the antiviral activity and safety of 3 month Fuzeon induction with an optimized background antiretroviral regimen versus OB alone, in Fuzeon-naive HIV-1 infected patients with virological failure

Trial Profile

A randomized, open-label study evaluating the antiviral activity and safety of 3 month Fuzeon induction with an optimized background antiretroviral regimen versus OB alone, in Fuzeon-naive HIV-1 infected patients with virological failure

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Enfuvirtide (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms INNOVE
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2012 Primary endpoint 'Virological-response-rate' has not been met.
    • 19 Sep 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top